XTL-Cand-MAb

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NameXTL-Cand-MAb
Drug Alias Namecandidiasis therapy (XTL)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsCandidiasis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIsrael
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesXtl Biopharmaceuticals Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesXtl Biopharmaceuticals Ltd
Active IndicationsN/A
Inactive IndicationsCandidiasis

Other Information

ATC CodeN/A
Related LinksN/A